Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 69 Breast Neoplasms 51 Carcinoma, Non-Small-Cell Lung 28 Neoplasms 27 Myelodysplastic Syndromes 27 Advanced Solid Tumors 27 Advanced Solid Tumor 26 Prostatic Neoplasms 23 Stomach Neoplasms 19 Recurrence 18 Multiple Myeloma 18 Neoplasm Metastasis 17 Carcinoma, Hepatocellular 17 Ovarian Neoplasms 15 Lung Neoplasms 15 Pancreatic Neoplasms 14 Uterine Cervical Neoplasms 13 Solid Tumor 13 Sarcoma 13 Melanoma 13 Leukemia, Myelomonocytic, Chronic 13 Colorectal Neoplasms 11 Triple Negative Breast Neoplasms 10 Small Cell Lung Carcinoma 10 Lymphoma, Large B-Cell, Diffuse 10 Squamous Cell Carcinoma of Head and Neck 8 Myeloproliferative Disorders 8 Lymphoma, Non-Hodgkin 8 Esophageal Neoplasms 8 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7

Interventions

Insulin Glargine 4 Insulin 3 volagidemab 2 Metformin 2 Fulvestrant 2 Alpelisib 2 ziprasidone 1 relacorilant 1 pembrolizumab 1 exemestane 1 dapagliflozin 1 Vildagliptin 1 Tamoxifen 1 Standard of Care 1 Olanzapine 1 Letrozole 1 Insulin Lispro 1 Insulin Aspart 1 Injections 1 DNA, Ribosomal 1 Blood Specimen Collection 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Hyperglycemia × Injections × Clear all

NCT02216799 2016-02-25

GLUCOSE-in-PN

King Faisal Specialist Hospital & Research Center

Phase 4 Completed

Hyperglycemia, Hyperphagia, Insulin Resistance

Data powered by HemOnc (CC BY 4.0) Colophon ⚡